Kisspeptin-10 and the HPG Axis: The Signal That Starts Puberty

Kisspeptin sits further upstream than almost any other peptide in circulation. Most compounds act on one tissue to produce one effect. Kisspeptin acts on the switch that starts an entire endocrine axis — and its discovery rewrote the textbook account of how puberty begins.

Found by working backwards from a disorder

The receptor came first. GPR54 (now also called KISS1R) was an orphan G-protein-coupled receptor with no known ligand until two research groups independently reported in 2003 that loss-of-function mutations in it caused idiopathic hypogonadotropic hypogonadism — a condition in which puberty does not start.

That established something specific: whatever activated this receptor was necessary for the reproductive axis to switch on at all. The ligand turned out to be a family of peptides from the KISS1 gene, cleaved into fragments of 54, 14, 13 and 10 amino acids. Kisspeptin-10 is the shortest fragment that retains full receptor activity.

The signalling cascade

Kisspeptin acts on GnRH neurons in the hypothalamus, which express KISS1R. Activating them triggers release of gonadotropin-releasing hormone into the hypophyseal portal circulation. GnRH acts on the anterior pituitary to release luteinising hormone and follicle-stimulating hormone, which act on the gonads to drive steroid production and gametogenesis.

So kisspeptin sits one step above GnRH, which is itself the top of the conventional hypothalamic-pituitary-gonadal cascade. Kisspeptin neurons are also where much of the feedback from circulating sex steroids is integrated, making them a control point rather than merely a relay.

Why the ten-amino-acid fragment

The KISS1 gene product is processed into several peptides — kisspeptin-54, -14, -13 and -10 — which share a common C-terminal decapeptide sequence. That shared C-terminus is the part that engages the receptor, which is why the shortest fragment retains full activity at KISS1R despite being a fifth the length of the longest.

The fragments are not interchangeable in practice, though. They differ in stability and clearance, and much of the published human work used kisspeptin-54 rather than -10. That is a detail worth carrying: results obtained with one fragment do not automatically describe another, and conflating them is a common error in secondary writing about this compound.

The KNDy neuron and pulse generation

Kisspeptin does not act alone. The hypothalamic neurons involved co-express kisspeptin, neurokinin B and dynorphin — abbreviated to KNDy neurons after those three signals. The prevailing model is that this population functions as the pulse generator for the whole axis: neurokinin B providing stimulatory drive within the network and dynorphin providing inhibition, with the interplay producing the rhythmic output that GnRH release requires.

This matters because the reproductive axis is not driven by absolute hormone levels but by pulse frequency. Continuous stimulation of the GnRH receptor downregulates it — a fact exploited clinically, where sustained GnRH agonism is used to suppress the axis rather than activate it. Any compound acting on this system has to be understood in terms of pattern, not merely presence.

Feedback integration

GnRH neurons themselves largely lack the receptor for oestrogen that would allow direct feedback. Kisspeptin neurons have it. This resolved a long-standing puzzle about how circulating sex steroids regulate their own upstream control, and it places kisspeptin at the point where feedback is actually integrated.

Two anatomically distinct kisspeptin populations appear to handle different halves of that job — one associated with the negative feedback that keeps the axis in range, another with the positive feedback that generates the pre-ovulatory surge. That functional split is part of why the system is of research interest well beyond the question of how puberty starts.

Why the human evidence is better than usual here

Unlike most compounds discussed on this site, kisspeptin has a substantial published human research programme, much of it from Imperial College London. Administration studies have reported increases in LH in both men and women, and the peptide has been investigated in reproductive medicine, including as an alternative trigger in assisted reproduction where the aim is to reduce a specific complication of conventional triggering.

Separate imaging work has examined kisspeptin's effects on brain regions involved in emotional and behavioural processing, suggesting the system is not purely reproductive.

Two caveats keep this in proportion. Most of these are small, controlled, mechanistic studies in defined populations, not large outcome trials. And kisspeptin's short half-life is a real constraint on how the peptide behaves — something to weigh against any claim extrapolated from a continuous-infusion protocol.

Status and handling

Kisspeptin-10 is not an approved medicine in Australia. TXLABS supplies it strictly as a research reference material for laboratory use only — not a medicine, not for human or veterinary use, and nothing here constitutes dosing guidance. Hormone-axis compounds sit within Schedule 4 territory under the Poisons Standard; see peptide regulations in Australia.

As a short peptide it is subject to the usual handling constraints — see reconstitution and storage in Australian conditions. Wider mechanistic context is on how peptides work.